Experimental Lung Cancer Drug Cuts Death Risk by 34% in Major Chinese Trial
Akeso and Summit Therapeutics report breakthrough results for ivonescimab in late-stage study, potentially offering new hope for patients with advanced lung cancer.
Read the full reporting at CNBC Markets.
Originally reported by CNBC Markets.